Hypercalcemia Clinical Presentation
- Author: Mahendra Agraharkar, MD, MBBS, FACP, FASN; Chief Editor: Vecihi Batuman, MD, FACP, FASN more...
History
The mnemonic "stones," "bones," "abdominal moans," and "psychic groans" describes the constellation of symptoms and signs of hypercalcemia. These may be due directly to the hypercalcemia, to increased calcium and phosphate excretion, or to skeleton changes. The history of hypercalcemia is dependent on its cause and the sensitivity of the individual to higher calcium levels. Individuals with mild prolonged hypercalcemia may have mild or no symptoms, or, they may have recurring problems such as kidney stones. Those with more sudden onset and severe hypercalcemia may experience dramatic symptoms, usually including confusion and lethargy, possibly leading quickly to death.
- Central nervous system effects include the following:
- Lethargy
- Weakness
- Confusion
- Coma
- Renal effects include the following:
- Polyuria
- Nocturia
- Dehydration
- Renal stones
- Renal failure
- Gastrointestinal effects include the following:
- Constipation
- Nausea
- Anorexia
- Pancreatitis
- Gastric ulcer
- Cardiac effects include syncope from arrhythmias.
Physical
Most patients with hypercalcemia do not have any specific findings upon physical examination. Those with higher calcium levels may have findings that are more striking. Evidence of the underlying cause may be found, such as a suggestive breast mass in someone with hypercalcemia secondary to malignancy.
- Nervous system findings include the following:
- Confusion
- Hypotonia
- Hyporeflexia
- Paresis
- Coma
- Renal findings include the following:
- Volume depletion
- Signs of renal failure
- Gastrointestinal findings include the following:
- Fecal impaction (from constipation)
- Signs of pancreatitis
- Signs of malignancy (eg, enlarged liver or masses)
- Cardiac findings include the following:
- Arrhythmias
- Hypotension
- Shortened QT interval
- General findings may include band keratopathy, which is calcium precipitation in a horizontal band across the cornea in the palpebral aperture.
Causes
Approximately 90% of cases of hypercalcemia are caused by malignancy or hyperparathyroidism. About 20-30% of patients with cancer have hypercalcemia during the course of the disease, and its detection may signify an unfavorable prognosis. Of the cases due to malignancy, approximately 80% are due to bony metastases, while the other 20% are due to PTHrP effects. Hypercalcemia secondary to malignancy may be classified into the following 4 types, based on the mechanism involved:
- Humoral hypercalcemia of malignancy (HHCM) from an increased secretion of PTHrP - Most common form, accounting for up to 80% of cases
- Osteolytic hypercalcemia from osteoclastic activity and bone resorption surrounding the tumor tissue - The second most common mechanism, accounting for about 20% of cases
- Secretion of active vitamin D by some lymphomas
- Ectopic PTH secretion - Very rare
The remaining 10% of cases of hypercalcemia are caused by many different conditions, including vitamin D–related problems, disorders associated with rapid bone turnover, thiazides or renal failure, and in rare cases, familial causes. Treatment with recombinant human parathyroid hormone for postmenopausal osteoporosis is also a cause.[5]
- Causes of hypercalcemia that are related to malignancy (lung, breast, and myeloma are the most common tumors) include the following:
- Solid tumor metastases
- Solid tumors with humoral effects
- Hematologic malignancies
- Causes of hypercalcemia that are related to the parathyroid include the following:
- Primary hyperparathyroidism
- Solitary adenoma
- Generalized hyperplasia
- Multiple endocrine neoplasia type 1 or type 2A
- Lithium-related release of PTH
- Familial cases of high PTH
- Primary hyperparathyroidism
- Those related to vitamin D include the following:
- Vitamin D toxicity[6]
- Granulomatous disease (especially sarcoidosis)
- Those related to high bone turnover include the following:
- Hyperthyroidism
- Immobilization (especially in Paget disease)
- Thiazides
- Vitamin A intoxication
- Renal failure (milk-alkali syndrome)
- Other causes related to particular mechanisms are as follows:
- Increased intestinal calcium absorption
- Idiopathic infantile hypercalcemia (Williams syndrome)
- Vitamin D intoxication
- Vitamin A intoxication
- Granulomatous disorders, eg, sarcoidosis
- Decreased renal calcium excretion
- Hyperparathyroidism
- Familial hypocalciuric hypercalcemia
- Thiazide diuretics
- Increased bone resorption
- Immobilization
- Hyperparathyroidism
- Malignancy
- Mutations of the calcium-sensing receptor
- Familial benign hypocalciuric hypercalcemia
- Neonatal severe hyperparathyroidism
- Uncertain mechanism
- Hypophosphatasia
- Subcutaneous fat necrosis
- Blue diaper syndrome
- Dietary phosphate deficiency
- Increased intestinal calcium absorption
McKay CP, Portale A. Emerging topics in pediatric bone and mineral disorders 2008. Semin Nephrol. Jul 2009;29(4):370-8. [Medline].
Guarnieri V, Canaff L, Yun FH, et al. Calcium-Sensing Receptor (CASR) Mutations in Hypercalcemic States: Studies from a Single Endocrine Clinic Over Three Years. J Clin Endocrinol Metab. Feb 17 2010;[Medline].
Nissen PH, Christensen SE, Wallace A, et al. Multiplex ligation-dependent probe amplification (MLPA) screening for exon copy number variation in the calcium sensing receptor gene: no large rearrangements identified in patients with calcium metabolic disorders. Clin Endocrinol (Oxf). Nov 11 2009;[Medline].
Alsirafy SA, Sroor MY, Al-Shahri MZ. Hypercalcemia in advanced head and neck squamous cell carcinoma: prevalence and potential impact on palliative care. J Support Oncol. Sep-Oct 2009;7(5):154-7. [Medline].
Luna-Cabrera F, Justicia-Rull EA, Caricol-Pérez MP, et al. Incidence of hypercalcemia, hypercalciuria and related factors in patients treated with recombinant human parathyroid hormone (1-84). Minerva Med. Apr 2012;103(2):103-10. [Medline].
Vanstone MB, Oberfield SE, Shader L, Ardeshirpour L, Carpenter TO. Hypercalcemia in Children Receiving Pharmacologic Doses of Vitamin D. Pediatrics. Mar 12 2012;[Medline].
Makras P, Papapoulos SE. Medical treatment of hypercalcaemia. Hormones (Athens). Apr-Jun 2009;8(2):83-95. [Medline]. [Full Text].
Bergenfelz AO, Jansson SK, Wallin GK, et al. Impact of modern techniques on short-term outcome after surgery for primary hyperparathyroidism: a multicenter study comprising 2,708 patients. Langenbecks Arch Surg. Jul 18 2009;[Medline].
Low TH, Clark J, Gao K, et al. Outcome of parathyroidectomy for patients with renal disease and hyperparathyroidism: predictors for recurrent hyperparathyroidism. ANZ J Surg. May 2009;79(5):378-82. [Medline].
Padhi D, Harris R. Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48(5):303-11. [Medline].
Marcocci C, Chanson P, Shoback D, et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab. Jun 2 2009;[Medline].
al Zahrani A, Levine MA. Primary hyperparathyroidism. Lancet. Apr 26 1997;349(9060):1233-8. [Medline].
Allerheiligen DA, Schoeber J, Houston RE. Hyperparathyroidism. Am Fam Physician. Apr 15 1998;57(8):1795-802, 1807-8. [Medline].
Carroll MF, Schade DS. A practical approach to hypercalcemia. Am Fam Physician. May 1 2003;67(9):1959-66. [Medline].
Falk S, Fallon M. ABC of palliative care. Emergencies. BMJ. Dec 6 1997;315(7121):1525-8. [Medline].
Ganong CA, Kappy MS. Hypercalcemia. In: Berman S, ed. Pediatric Decision Making. 3rd ed. St. Louis, Mo: Mosby-Year Book; 1996:. 128-31.
Hay WW Jr, Hayward AR, Levin MJ, Sondheimer JM, eds. Current Pediatric Diagnosis and Treatment. 14th ed. Stamford, Conn: Appleton & Lange; 1999:. 830-1.
Hoenderop JG, Nilius B, Bindels RJ. Molecular mechanism of active Ca2+ reabsorption in the distal nephron. Annu Rev Physiol. 2002;64:529-49. [Medline].
Inzucchi SE. Management of hypercalcemia. Diagnostic workup, therapeutic options for hyperparathyroidism and other common causes. Postgrad Med. May 2004;115(5):27-36. [Medline].
Lteif AN, Zimmerman D. Bisphosphonates for treatment of childhood hypercalcemia. Pediatrics. Oct 1998;102(4 Pt 1):990-3. [Medline].
Mundy GR, Guise TA. Hypercalcemia of malignancy. Am J Med. Aug 1997;103(2):134-45. [Medline].
Pearce SH. Calcium homeostasis and disorders of the calcium-sensing receptor. J R Coll Physicians Lond. Jan-Feb 1998;32(1):10-4. [Medline].
Postlethwaite RJ. Clinical Pediatric Nephrology. 2nd ed. New York, NY: Butterworth Heinemann; 1994.
Renton P. Radiology of rickets, osteomalacia and hyperparathyroidism. Hosp Med. May 1998;59(5):399-403. [Medline].
Rogers MJ, Watts DJ, Russell RG. Overview of bisphosphonates. Cancer. Oct 15 1997;80(8 Suppl):1652-60. [Medline].
Sharma OP. Vitamin D, calcium, and sarcoidosis. Chest. 1996;109(2):535-539. [Medline].
Strewler GJ. The physiology of parathyroid hormone-related protein. N Engl J Med. Jan 20 2000;342(3):177-85. [Medline].

